Mehadrin (TASE:MEDN) Stock Faces Profit Squeeze Despite Low P/E

The market has Mehadrin stock roughly flat over the past week while the 3 month trend is weaker, yet the latest earnings tell a more complicated story. Q2 revenue came in at ₪282.079 million with basic earnings per share of ₪0.75, a sharp step down from the strong Q1 print. At the same time, the trailing 12 month picture still shows very large year on year earnings growth and a P/E of 7.4x, well below peers. The tension between that low valuation and the recent profit squeeze is what drove today’s sentiment reset.

Like Mehadrin’s low 7.4x P/E but uneasy about the recent profit squeeze after Q2 earnings? Check out 277 high quality undervalued stocks for stocks that combine modest valuations with stronger recent earnings momentum.

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs. Q2 2025): ₪282.079 million vs. ₪236.718 million (up about 19%)
• Net Income (Excl. Extra Items, Q2 2026 vs. Q2 2025): ₪2.593 million vs. a loss of ₪0.299 million (swing back to profit)
• Basic EPS (Q2 2026 vs. Q2 2025): ₪0.75 vs. a loss of ₪0.09 (swing back to positive earnings per share)
• Trailing 12 Month Net Margin (to Q2 2026 vs. prior year): 9.3% vs. 1.5% (very large improvement in profitability)

Prefer clean visuals instead of combing through dense earnings tables and footnotes for Mehadrin? View the full picture of Mehadrin’s valuation in an intuitive set of charts with the company report for Mehadrin.

Mehadrin: Earnings Momentum Behind the Defensive Story

For investors drawn to Mehadrin as a defensive food and real asset play, the latest numbers still support parts of that story. Revenue of ₪282.079 million in Q2 2026 compares favourably with Q2 2025. Net income swung from a loss to a profit and trailing 12 month net margin of 9.3% is higher than 1.5% a year earlier. That combination suggests the core business model is currently converting a larger share of sales into profit, which fits a thesis that essential produce and infrastructure can support more resilient earnings.

Mehadrin: Recent Profit Squeeze Keeps Risks Visible

The bearish angle around Mehadrin focuses on operational and earnings volatility and the recent profit squeeze in Q2 keeps that concern alive. Basic EPS dropped to ₪0.75 compared with a much stronger Q1, while the share price is down about 6% over 30 days and about 14% over 90 days. These moves indicate the market is treating recent margin pressure seriously. Even with better trailing profitability, the near term step down in quarterly earnings shows that agricultural and export risks remain a tangible part of the story.

After a quarter where Mehadrin showed both improved trailing margins and a fresh squeeze on recent earnings, investors may wonder if weaker cash coverage of debt and high non cash earnings are early warnings or a sign of deeper fragility. Review our independent risk analysis for Mehadrin which shows 3 important warning signs

Stay Ahead With Simply Wall St

If Mehadrin’s low P/E and recent profit squeeze have your attention, register for free with Simply Wall St and add it to your Watchlist to track the share price against fair value and watch for a better entry point. Once you decide to take a position, keep your focus on what matters by using the Portfolio Command Center to cut through noise and surface only key developments that may affect your thesis. For a longer term view, use the Community to see how other investors are thinking about Mehadrin and similar stocks. This way you can spot potential catalysts or emerging risks early and stay a step ahead of the market.

Seeking Alternatives Beyond Mehadrin Stock

Fresh ideas can move quickly. Some stocks are building breakout momentum while they are still under the radar for now. Do not get caught reacting late, consider acting earlier instead.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com